SML2733
RLA8
≥98% (HPLC)
Synonym(s):
8-[3-Methoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]phenoxy]octanoic acid
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
protect from light
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
RLA8 is an orally available and potent agonist of peroxisome proliferator-activated receptors (PPARs)-α/γ/δ and G-protein-coupled receptor 40 (GPR40). RLA8 reverses the proregression of pathological changes such as hepatic lipid accumulation, steatosis, inflammation and fibrosis in mice models of nonalcoholic steatohepatitis (NASH). Also, it improves serum HDL cholesterol, reduce hepatic free fatty acid and triglyceride levels, and alleviate insulin resistance.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
The Journal of pharmacology and experimental therapeutics, 369(1), 67-77 (2019-02-13)
Nonalcoholic fatty liver disease (NAFLD) is a very common chronic hepatic disease, with nonalcoholic steatohepatitis (NASH) as a major and severe subcategory that can lead to cirrhosis and hepatocellular carcinoma, and thereby to a high mortality rate. Currently, there has
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service